Baidu
map

Sci Rep:胚胎特异性蛋白1(PLAC1)是抗体-药物结合治疗前列腺癌免疫疗法的潜在靶标

2017-10-18 AlexYang MedSci原创

之前,有研究人员指出他们的发现强烈的支持了PLAC1可作为前列腺癌(PCa)免疫疗法靶标的想法。最近,他们制作并评估了基于抗胚胎特异性蛋白1(PLAC1)的抗体药物结合体(ADC)对前列腺癌的靶标免疫治疗。研究发现,前列腺癌细胞表达出了可观的PLAC1水平。PLAC1克隆抗体2H12C12在前列腺细胞中表现出了与重组PLAC1高度的反映力和对PLAC1的选择性识别,但是在阴性对照LS180细胞中并

之前,有研究人员指出他们的发现强烈的支持了PLAC1可作为前列腺癌(PCa)免疫疗法靶标的想法。最近,他们制作并评估了基于抗胚胎特异性蛋白1(PLAC1)的抗体药物结合体(ADC)对前列腺癌的靶标免疫治疗。

研究发现,前列腺癌细胞表达出了可观的PLAC1水平。PLAC1克隆抗体2H12C12在前列腺细胞中表现出了与重组PLAC1高度的反映力和对PLAC1的选择性识别,但是在阴性对照LS180细胞中并没有表现出上述现象。PLAC1结合体在几分钟内诱导了抗体快速的内化,并且在15分钟是达到50%,在1个小时内几乎达到了100%。当SN38与抗体结合时,抗体药物偶联(DAR)比例达到了5.5,并且抗体对细胞表面抗原的亲和力没有消极影响。另外,ADC保留了内在抗体的活性,并且表现出了增强的和选择性的细胞毒性,即62nM时为IC50,这个数据要比自由药物低15倍。抗PLAC1 ADC在人类初级前列腺癌细胞和前列腺细胞系中可以诱导细胞凋亡,并且在体内动物安全试验中并没有观察到明显的细胞毒性影响。最后,研究人员指出,他们新开发的基于抗PLAC1的ADCs也许为PCa病人的免疫治疗提供了可依赖的、有效的和新的治疗方法。

原始出处:

Mohammad-Reza Nejadmoghaddam, Amir-Hassan Zarnani, Ramin Ghahremanzadeh et al. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy. Sci Rep. 17 Oct 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798051, encodeId=96c01e98051be, content=<a href='/topic/show?id=cc206e96084' target=_blank style='color:#2F92EE;'>#特异性蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67960, encryptionId=cc206e96084, topicName=特异性蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 18 09:27:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899161, encodeId=569d189916183, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jan 10 06:27:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257268, encodeId=2ff325e2684c, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Oct 30 18:47:51 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315363, encodeId=c7db13153635c, content=<a href='/topic/show?id=6fcc83e0554' target=_blank style='color:#2F92EE;'>#胚胎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83705, encryptionId=6fcc83e0554, topicName=胚胎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352781, encodeId=47121352e815e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254120, encodeId=3d7f25412049, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:40:59 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798051, encodeId=96c01e98051be, content=<a href='/topic/show?id=cc206e96084' target=_blank style='color:#2F92EE;'>#特异性蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67960, encryptionId=cc206e96084, topicName=特异性蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 18 09:27:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899161, encodeId=569d189916183, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jan 10 06:27:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257268, encodeId=2ff325e2684c, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Oct 30 18:47:51 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315363, encodeId=c7db13153635c, content=<a href='/topic/show?id=6fcc83e0554' target=_blank style='color:#2F92EE;'>#胚胎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83705, encryptionId=6fcc83e0554, topicName=胚胎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352781, encodeId=47121352e815e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254120, encodeId=3d7f25412049, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:40:59 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798051, encodeId=96c01e98051be, content=<a href='/topic/show?id=cc206e96084' target=_blank style='color:#2F92EE;'>#特异性蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67960, encryptionId=cc206e96084, topicName=特异性蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 18 09:27:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899161, encodeId=569d189916183, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jan 10 06:27:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257268, encodeId=2ff325e2684c, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Oct 30 18:47:51 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315363, encodeId=c7db13153635c, content=<a href='/topic/show?id=6fcc83e0554' target=_blank style='color:#2F92EE;'>#胚胎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83705, encryptionId=6fcc83e0554, topicName=胚胎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352781, encodeId=47121352e815e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254120, encodeId=3d7f25412049, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:40:59 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-30 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1798051, encodeId=96c01e98051be, content=<a href='/topic/show?id=cc206e96084' target=_blank style='color:#2F92EE;'>#特异性蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67960, encryptionId=cc206e96084, topicName=特异性蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 18 09:27:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899161, encodeId=569d189916183, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jan 10 06:27:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257268, encodeId=2ff325e2684c, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Oct 30 18:47:51 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315363, encodeId=c7db13153635c, content=<a href='/topic/show?id=6fcc83e0554' target=_blank style='color:#2F92EE;'>#胚胎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83705, encryptionId=6fcc83e0554, topicName=胚胎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352781, encodeId=47121352e815e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254120, encodeId=3d7f25412049, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:40:59 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-20 ailian1202
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798051, encodeId=96c01e98051be, content=<a href='/topic/show?id=cc206e96084' target=_blank style='color:#2F92EE;'>#特异性蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67960, encryptionId=cc206e96084, topicName=特异性蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 18 09:27:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899161, encodeId=569d189916183, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jan 10 06:27:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257268, encodeId=2ff325e2684c, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Oct 30 18:47:51 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315363, encodeId=c7db13153635c, content=<a href='/topic/show?id=6fcc83e0554' target=_blank style='color:#2F92EE;'>#胚胎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83705, encryptionId=6fcc83e0554, topicName=胚胎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352781, encodeId=47121352e815e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254120, encodeId=3d7f25412049, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:40:59 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1798051, encodeId=96c01e98051be, content=<a href='/topic/show?id=cc206e96084' target=_blank style='color:#2F92EE;'>#特异性蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67960, encryptionId=cc206e96084, topicName=特异性蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Apr 18 09:27:00 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899161, encodeId=569d189916183, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jan 10 06:27:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257268, encodeId=2ff325e2684c, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Mon Oct 30 18:47:51 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315363, encodeId=c7db13153635c, content=<a href='/topic/show?id=6fcc83e0554' target=_blank style='color:#2F92EE;'>#胚胎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83705, encryptionId=6fcc83e0554, topicName=胚胎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352781, encodeId=47121352e815e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Oct 20 12:27:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254120, encodeId=3d7f25412049, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed Oct 18 21:40:59 CST 2017, time=2017-10-18, status=1, ipAttribution=)]
    2017-10-18 惠映实验室

    学习了.谢谢.

    0

相关资讯

J Urol: 前列腺癌发生率和前列腺特异抗原筛选流行度分析

在美国国家预防服务工作组(USPSTF)推荐的预防常规PSA工作之后,前列腺特异性抗原(PSA)筛选和前列腺癌发生率的减少是否与社会经济组织和美国人口普查区域之间是相似的这个问题仍旧不清楚。最近,有研究人员通过调查年龄、种族、疾病阶段、美国地区和区域社会经济状态分析了前列腺癌发生率和PSA筛选流行度。研究人员调查了年度百分比变化速率,并计算了边际概率和95%置信区间(CI)来评估PSA筛选流行度变

Eur Urol:淋巴结阳性前列腺癌患者根治性前列腺切除术后生存结局:不同术后管理策略的比较分析。

在本研究中,研究者评估了三种不同的管理策略与根治性前列腺切除术后发生淋巴结转移的患者的生存关系。

治疗特定前列腺癌,**新药有望近期上市

杨森(Janssen)公司今天宣布,该公司已经向FDA提交了一份新药申请,使用apalutamide(ARN-509),一款下一代口服雄激素受体抑制剂(AR),治疗非转移性去势抵抗性前列腺癌。目前,尚没有FDA批准的疗法针对此类疾病。

Eur Urol:比较醋酸阿比特龙和多西他赛联合雄激素剥夺治疗在高风险和转移性未经激素治疗的前列腺癌中的作用:系统评价与荟萃分析。

最近,随机临床试验已经验证了在使用激素剥夺疗法(ADT,使用波尼松/泼尼松龙)治疗未经激素治疗的晚期前列腺癌(PCa)时联合多西他赛或阿比特龙的益处。

Prostate:白花丹素可以提高治疗前列腺癌的雄激素疗法阻断效果

白花丹素是治疗前列腺癌的候选药物。之前的研究表明了白花丹素也许可以提高雄激素阻断疗法(ADT)的治疗效果。最近,有研究人员评估了将白花丹素和ADT结合在前列腺癌小鼠模型中进行试验,从而支持白花丹素的临床应用。研究人员利用新的芝麻油配方进行白花丹素口腔服用,并在小鼠中进行了标准的毒性研究。对肿瘤生长研究,研究人员将小鼠前列腺癌细胞团嫁接到前列腺组织上来形成肿瘤。小鼠被分成不同处理的小组,肿瘤大小通过

Cancer Lett:卡巴他赛聚合物纳米粒子可以用来治疗多烯紫杉醇抗性和骨转运前列腺癌

转移性去势难治性前列腺癌(mCRPC)有效的治疗到目前为止仍旧是一个挑战。卡巴他赛(CBZ)是被批准用于多烯紫杉醇治疗失败的药物,但是生存期的改善仅仅只有大约2个月,并且病人要承受显著的负作用。最近,有研究人员报道了一个关于卡巴他赛的基于聚合物传递系统的开发和研究,目的是提高卡巴他赛的安全性和对DTX抗性mCRPC治疗的有效性。CBZ结合到一种羧甲基纤维素聚合物上(Cellax-CBZ),并且可以

Baidu
map
Baidu
map
Baidu
map